Related Experiment Video
Updated: Jul 23, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.4K
Allosteric modulator potentiates β2AR agonist-promoted bronchoprotection in asthma models
Seungkirl Ahn1, Harm Maarsingh2, Julia Kl Walker1,3
1Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
The Journal of Clinical Investigation
|July 11, 2023
Summary
A novel compound, compound-6 (Cmpd-6), acts as a positive allosteric modulator (PAM) for beta-2 adrenergic receptors (β2ARs). Cmpd-6 enhances β2-agonist effectiveness in protecting airways, showing promise for treating asthma and similar respiratory conditions.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Molecular Biology
Background:
- Asthma is a chronic inflammatory airway disease characterized by episodic narrowing.
- Current inhaled beta-2 adrenergic receptor (β2AR) agonists offer limited efficacy in bronchodilation.
- All approved β2-agonists are orthosteric ligands binding to the same site as epinephrine.
Purpose of the Study:
- To investigate the therapeutic potential of a novel β2AR-selective positive allosteric modulator (PAM), compound-6 (Cmpd-6).
- To assess the impact of Cmpd-6 on β2AR-mediated bronchoprotection in preclinical models and human tissues.
Main Methods:
- Characterization of Cmpd-6 binding to β2ARs in guinea pig, mouse, and human systems.
- Assessment of Cmpd-6's effect on β2-agonist-induced signaling and downstream effects.
- Evaluation of Cmpd-6's efficacy in preventing methacholine- and allergen-induced bronchoconstriction in lung slices.
Main Results:
- Cmpd-6 allosterically potentiated β2-agonist binding and signaling in guinea pig and human β2ARs, but not murine β2ARs.
- Cmpd-6 enhanced β2-agonist-mediated bronchoprotection against methacholine challenge in guinea pig and human lung slices.
- The compound demonstrated efficacy in a guinea pig model of allergic asthma, improving β2-agonist function.
Conclusions:
- β2AR-selective PAMs, such as Cmpd-6, represent a promising therapeutic strategy for asthma.
- Allosteric modulation offers a novel approach to enhance bronchodilation and airway protection.
- Further research into PAMs could lead to improved treatments for obstructive respiratory diseases.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
311
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
311
01:24Antiasthma Drugs: Methylxanthines
272
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
272
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
345
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
345
01:20Asthma: Pathogenesis and Management
450
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
450
01:19Antiasthma Drugs: Leukotriene Modifiers
368
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
368
01:26COPD: Management Using Bronchodilators and Corticosteroids
249
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
249